A Phase 2, Open-label, Dose-escalation Study to Evaluate Pharmacokinetics, Pharmacodynamics, Bioavailability, Safety, and Tolerability of TLC590 in Multiple Surgical Models
Latest Information Update: 02 Sep 2024
At a glance
- Drugs Ropivacaine (Primary)
- Indications Postoperative pain
- Focus Adverse reactions
- Sponsors Taiwan Liposome Company
- 02 Sep 2024 New trial record